April 25, 2024
Authored and Edited by Anna B. Chauvet; Maxime I. Jarquin
The creative promise of generative artificial intelligence (“GenAI or “AI”) is tremendous. Irrespective of artistic talent, any user can enter a text prompt into an AI tool and generate a new visual or audio work. Such AI tools also allow for the creation of outputs that impersonate the voice, image, or other likeness of individuals. Currently, no federal “right of publicity” exists in the United States protecting an individual’s name, likeness, or other recognizable aspects of one’s persona from commercial misappropriation (such as use in advertising). A majority of states, however, recognize such a right of publicity. These state laws typically contain carveouts to protect expressive speech under the First Amendment, such as for artistic expression in film and TV.
In a recent case, Main Sequence Ltd. v. Dudesy, LLC, the estate of late stand-up comedian George Carlin sued a podcast company right of publicity violations and copyright infringement after the company published an AI-generated comedy special allegedly impersonating Carlin’s voice, likeness, and comedic style. Although the parties recently settled the case, the issues raised in this lawsuit remain highly relevant to ongoing policy discussions and legislative efforts to address the use of AI to impersonate the voice, image, or other likeness of individuals.
Read more on Main Sequence Ltd.v. Dudesy, LLC here.
Copyright © 2024 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Webinar
Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement
May 18, 2026
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.